Drug Trial Radar · NCT05408221
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
576
Planned (sponsor's estimate)
Start
Nov 11, 2022
Primary completion
Aug 1, 2025
Study completion Aug 1, 2026
Sponsor
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .
Conditions
- Hepatocellular Carcinoma
Interventions
Rulonilimab+LenvatinibDrug
Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
Rulonilimab placebo +LenvatinibDrug
Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: From randomization to PR or CR.Up to approximately 35 months.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Huizhou Central People's Hospital
Guandong, China · Recruiting
Jinan Central Hospital
Shandong, China · Recruiting
Linyi Cancer Hospital
Shandong, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.